Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06743126 · ClinicalTrials.gov registry record · Phase 3
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
A Phase 3 study of Melanoma, Cutaneous Malignant, sponsored by Immatics US.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 360
- Enrollment target
- 20
- Study locations
NCT06743126: Recruiting Phase 3 study of Melanoma, Cutaneous Malignant, sponsored by Immatics US.
NCT06743126 is a Phase 3 study of Melanoma, Cutaneous Malignant that is actively recruiting participants, run by Immatics US. The registered enrollment target is 360 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (53% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06743126, a Phase 3 study of Melanoma, Cutaneous Malignant, is actively recruiting participants, sponsored by Immatics US.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 360 participants
- Enrollment target
- 20
- Study locations
Study Summary
This clinical trial is a prospective, multicenter, open-label, randomized, actively controlled, parallel-group Phase 3 clinical trial to evaluate the efficacy, safety and tolerability of treatment with IMA203 administered at the recommended phase 2 dose versus investigator's choice of treatment in patients with previously treated, unresectable or metastatic cutaneous melanoma. For patients interested in additional information on how to participate, please follow this link: https://mytomorrows.com/trials/suprame/en-us/
Primary Outcome
progression-free survival (PFS), centrally assessed (by blinded independent central review) using RECIST 1.1
Conditions Studied
Interventions
- BIOLOGICAL pembrolizumab
- BIOLOGICAL IMA203
- BIOLOGICAL nivolumab plus relatlimab
- BIOLOGICAL lifileucel
- BIOLOGICAL nivolumab
Study Locations (20)
California
- City of Hope National Medical Center - Duarte
- UC San Diego Moores Cancer Center - La Jolla
- UCLA Hematology/Oncology - Los Angeles
- UCSF Helen Diller Family Comprehensive Cancer Center - San Francisco
- Stanford Cancer Center - Stanford
Florida
- Mayo Clinic Florida - Jacksonville
- University of Miami - Sylvester Comprehensive Cancer Cente - Miami
- Moffitt Cancer Center - Tampa
Arizona
- Mayo Clinic - Phoenix
- Honor Health Research Institute - Scottsdale
Massachusetts
- Massachusetts General Hospital - Boston
- Beth Israel Deaconess Medical Center - Boston
Colorado
- The University of Colorado, Anschutz Medical Campus - Aurora
Connecticut
- Yale Cancer Center - New Haven
Illinois
- University of Chicago Medical Center - Chicago
Maryland
- University of MD Greenebaum Comprehensive Cancer Center - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 360 participants |
| Start Date | 2025-01-14 |
| Est. Completion | 2031-10 |
| Phase | Phase 3 |
What NCT06743126 shows while recruiting
NCT06743126 is an interventional study that assigns participants to a tested intervention. The registered 360 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (53% lower).
The record links to 1 condition, with Melanoma, Cutaneous Malignant appearing as the primary indexed condition, and to 5 interventions - of which pembrolizumab is the first listed.
NCT06743126 names 20 study sites across 12 states, led by California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT06743126 about?
NCT06743126 is a clinical study titled "SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma". This clinical trial is a prospective, multicenter, open-label, randomized, actively controlled, parallel-group Phase 3 clinical trial to evaluate the efficacy, safety and tolerability of treatment with IMA203 administered at the recommended phase 2 dose versus investigator's choice of treatment in p...
What is the current status of trial NCT06743126?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 360 participants. The study started on 2025-01-14. Estimated completion is 2031-10.
What conditions does trial NCT06743126 study?
This clinical trial studies the following conditions: Melanoma, Cutaneous Malignant.
What interventions are being tested in trial NCT06743126?
The interventions under investigation include: pembrolizumab (BIOLOGICAL), IMA203 (BIOLOGICAL), nivolumab plus relatlimab (BIOLOGICAL), lifileucel (BIOLOGICAL), nivolumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT06743126?
This trial is sponsored by Immatics US, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06743126 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06743126's enrollment target sits among peer trials
360 1009th of 2000 higher than 980 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02747836 · 360 participants
Ultrasound Analysis of Human Carpal Tunnel System
- NCT04089046 · 360 participants · NA
Telemedicine Enhanced Asthma Management - Uniting Providers for Teens (TEAM-UP for Teens)
- NCT04130503 · 360 participants · NA
The Recovery in Stroke Using PAP Study
- NCT04160000 · 360 participants · Phase 4
Treatment Of Atrial Fibrillation In Preserved Cardiac Function Heart Failure
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI